1
|
Marin L, Vitagliano A, Russo A, Esposito F, Della Vella M, Ambrosini G, Andrisani A. P-327 The impact of chronic endometritis disease on endometrial receptivity gene expression in women with repeated implantation failure. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does chronic endometritis (CE) have an impact on the expression of the genes involved in the embryo implantation?
Summary answer
The mRNA expression of genes involved in embryo implantation (HOXA10, HOXA11, BTEB1 and LIF) does not change in patients with and without CE.
What is known already
CE is an inflammatory disorder of the endometrium with a detrimental effect on embryo implantation and its prevalence in women with repeated implantation failure (RIF) is up to 30%. During the implantation window, the expression of some genes plays a key role in determining the success of embryo implantation. The homeobox genes HOXA10, HOXA11 and the basic transcriptional element binding protein 1 (BTEB1) gene are essential for endometrial cells growth regulation and for embryonic development and the leukaemia inhibitory factor (LIF) has a role in the embryo–endometrium interaction.
Study design, size, duration
A single centre-prospective case-control study was conducted at the Women’s and Children’s Health Department at Padua University, on infertile women with RIF from June 2020 to November 2021. 29 women with RIF were prospectively enrolled.
Participants/materials, setting, methods
An endometrial biopsy using a Novak curette was performed for each patient and the obtained tissue samples were divided in two aliquots, one for immunohistochemistry for histological examination (endometrial dating and CE diagnosis) and one for RNA extraction and gene expression analysis that has been performed using RT-PCR. Sample of patients with and without CE were compared using non-parametric Mann–Whitney U-test. A p-value <.05 was considered as statistically significant.
Main results and the role of chance
Enrolled women were divided in two groups according to the histological diagnosis of CE: 13 patients with CE, 16 without CE. In all samples, appropriate histological dating (WOI) was evaluated according to Noyes criteria. After the comparison of all investigated genes (HOXA10, HOXA11, BTEB1 and LIF), no significant difference in mRNA expression was detected between women with and without CE (p value >.05). In the literature, defective endometrial expression of HOXA10, HOXA11 and LIF genes has been associated with abnormal implantation and the reduced expression of BTEB1 gene results in subfertility and progesterone resistance. Although the negative role of CE in altering embryo implantation is known, our results suggest that the CE has no effect on the expression of HOXA10, HOXA11, BTEB1 and LIF genes. Probably the detrimental effect of CE on embryo implantation does not act through HOXA10, HOXA11, BTEB1 and LIF gene expression.
Limitations, reasons for caution
This is a non-randomized observational study with a limited number of patients. Further studies are needed to confirm our data with immunohistochemistry evaluation to define the protein expression levels of the investigated genes.
Wider implications of the findings
Understanding the pathogenic mechanism of CE on endometrial receptivity is crucial for identifying markers that best correlate with possible implantation failure and for identifying the appropriate therapy to treat the disease and restore the embryo implantation capacity.
Trial registration number
not applicable
Collapse
Affiliation(s)
- L Marin
- University of Padua, Department of Women's and Children's Health , Padova, Italy
| | - A Vitagliano
- University of Padua, Department of Women's and Children's Health , Padova, Italy
| | - A Russo
- University of Padua, Department of Women's and Children's Health , Padova, Italy
| | - F Esposito
- Padua Hospital, Department of Women's and Children's Health , Padova, Italy
| | - M Della Vella
- University of Padua, Department of Women's and Children's Health , Padova, Italy
| | - G Ambrosini
- University of Padua, Department of Women's and Children's Health , Padova, Italy
| | - A Andrisani
- University of Padua, Department of Women's and Children's Health , Padova, Italy
| |
Collapse
|
2
|
Riviello E, Riva A, Bottai A, Buzzaccarini G, Marin L, Noventa M, Dell. Vella E, Coronella ML, Ambrosini G, Andrisani A. P–401 Frozen-thawed embryo-transfer adjuvant therapy: one size DOES NOT fit all. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Does adjuvant therapy after frozen-thawed embryo-transfer (FRET) with CardioAspirin and Prednisone enhance clinical pregnancy rate (CPR) and live birth rate (LBR)?
Summary answer
Adjuvant therapy enhanced CPR and LBR in study-group. A significant correlation was found confronting blastocyst FRET in study-group versus controls.
What is known already
Embryo implantation is a rate-limiting step of FRET cycles. It’s a complex process resulting from a balance between inflammation pathways and maternal immune tolerance. Low-dose aspirin unlocks Prostaglandin-F2 synthesis by Cyclooxygenase–1, thus increasing uterine vascular permeability and attachment reaction while reducing vasoconstriction. Pregnancy results from a balance between helper and regulatory T-cells (Treg), the latter protect the embryo from maternal immune attack. Treg cells’ immunosuppressive function is pivotal in pregnancy establishment. Prednisone increases the proportion of Treg cells thus inhibiting inflammation. Many therapy schedules for implantation enhancement are currently used worldwide, although there is no consistent shared evidence.
Study design, size, duration
Retrospective cohort-control study including 237 subjects who underwent FRET after artificial endometrial-preparation from January 2018 to March 2020. Estrogenic stimulation was either oral or transdermic. The study-group received luteal support (vaginal Progesterone 600 mg/die) and adjuvant therapy (CardioAspirin and Prednisone 25–5 mg); the control-group received luteal support only. Pregnancy test (PT) was scheduled 10–14 days post-transfer (blastocysts or cleavage stage embryos). Second PT and ultrasound were performed 7 days later if the first was positive.
Participants/materials, setting, methods
Patients referred to Padua University Hospital’s Human Reproduction Pathophysiology Unit. Exclusion criteria: >50/<18 years, fresh embryo-transfer cycles, oocyte-thawing cycles, natural/natural-modified cycles. Male factor was the prevalent fertility issue. Single embryo-transfer was performed in both groups. Mean endometrial thickness was 9 mm trilaminar in both groups. Statistical analysis were carried out using JMP Pro 14 software. Categorical variables were analyzed using Chi-square test or Fisher’s exact test where appropriate.
Main results and the role of chance
In the study-group, 87 subjects were given luteal support and adjuvant therapy, while in the control-group, 150 subjects received luteal support only. Groups were homogeneous for age, number of embryos transferred, endometrial thickness, endometrial features (trilaminarity) and fertilization tecniques (108 IVF/ 127 ICSI). CPR and LBR were significantly higher in the study-group. CPR was 31.4% in study-group versus 14.8% in controls (p = 0.002), LBR was 27.4% in study-group versus 11.6% in controls (p = 0.002). Since heterogeneity between groups was found regarding the type of embryo transferred (55.3% cleavage-stage versus 44.7% blastocyst, p < 0.01), the groups were split analyzed basing upon the type if embryo transferred. In the cleavage-stage FRET condition no relevant correlation was found between groups. However in blastocyst-FRET group CPR (34.5% study-group versus 18% controls, p = 0.04) and LBR (30.9% study-group versus 12% controls, p = 0.017) were significantly higher in the study-group, thus showing that adjuvant therapy could improve CPR and LBR.
Limitations, reasons for caution
Limited sample size negatively impacts the study’s power. It would be appropriate to expand the sample to obtain more reliable results.
Wider implications of the findings: Although no unanimous consent exists for tout-court adjuvant therapy administration, scientific literature shows that such therapy can help patients with repeated implantation failures or anti-nuclear-antibodies positivity. Assuming that a single-therapy-regimen could perfectly fit all patients is not realistic. We have to move towards patient-tailored adjuvant therapy thinking.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- E Riviello
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - A Riva
- Azienda Ospedaliera di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - A Bottai
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - G Buzzaccarini
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - L Marin
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - M Noventa
- Azienda Ospedaliera di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - E Dell. Vella
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - M L Coronella
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - G Ambrosini
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| | - A Andrisani
- Università degli Studi di Padova, Ginecologia e Ostetricia, Padova, Italy
| |
Collapse
|
3
|
Spagnol G, Bonaldo G, Marchetti M, Vitagliano A, Laganà AS, Scioscia M, Andrisani A, Ambrosini G, D’Antona D, Riva A, Saccardi C, Noventa M. O-140 Uterine septum: clinical implications on fertility and obstterics outcomes. A systematic review and meta-analysis. Hum Reprod 2021. [DOI: 10.1093/humrep/deab126.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Study question
How does the septate uterus and his metroplasty influence pregnancy rate (PR), live birth rate (LBR), spontaneous abortion rates (SA) and preterm labour rates (PL)?
Summary answer
Uterine septum is associated with a poor reproductive outcome. Metroplasty reduce the rate of SA but non-conclusive evidence can be extrapolated about PR and PL.
What is known already
Different studies evaluated the correlation between uterine septum and reproductive outcomes. On one hand, studies reported its association with poor obstetrics outcomes. On the other hand, recent studies raised doubts about the effectiveness of septum metroplasty to improve reproductive outcomes, although recent position papers continue to propose metroplasty in patients with a septate uterus and a history of infertility or miscarriages. Debate is still ongoing on reproductive outcomes of uterine septum on infertile patients and especially on patients with recurrent miscarriage, leading to an unanswered question whether or not these women should be treated.
Study design, size, duration
Systematic review and meta-analysis of published studies that evaluated the clinical impact of uterine septum and its metroplasty on reproductive and obstetrics outcomes. The meta-analysis included study with infertile patients or patients with a history of recurrent miscarriage.
Searches were conducted using the following search terms: uterine septum, septate uterus, metroplasty, pregnancy rate, live birth rate, spontaneous miscarriage, infertility, preterm delivery. Primary outcomes were PR and LBR. Secondary outcomes were SA and PL.
Participants/materials, setting, methods
The meta-analysis was written following the PRISMA guidelines. Fifty-nine full-text articles were preselected based on title and abstract. Endpoints were evaluated in three subgroups: 1) infertile/recurrent miscarriage patients with septum versus no septum 2) infertile/recurrent miscarriage patients with treated versus untreated septum 3) infertile/recurrent miscarriage patients before-after septum removal. Odds-ratios (OR) with 95% confidence intervals (CI) were calculated for outcome measures. Random-effect meta-analysis was performed and a p-value less than 0.05 was considered statistically significant.
Main results and the role of chance
Data from 37 articles were extracted. In the first subgroup (10 studies), a lower PR and LBR were associated with septate uterus vs. controls, respectively (OR 0.39, 95% CI 0.26 to 0.58; p < 0.000; low-heterogeneity and OR 0.21, 95% CI 0.12 to 0.39; p < 0.0001; small-heterogeneity) and a higher proportion of SA and PL was associated with septate uterus vs. controls, respectively (OR 4.17, 95% CI 2.83 to 6.15; p < 0.000; moderate-heterogeneity and OR 2.18, 95% CI 1.27 to 3.76; p = 0.005; low-heterogeneity). In the second subgroup (8 studies), PR and PL were not different in removed vs. unremoved septum, respectively (OR 1.10, 95% CI 0.49 to 2.49; p = 0.82; moderate heterogeneity and OR 0.44, 95% CI 0.18 to 1.08; p = 0.08;low-heterogeneity) and a lower proportion of SA was associated with removed vs. unremoved septum (OR 0.40, 95% CI 0.17 to 0.95; p = 0.001; substantial-heterogeneity). In the third subgroup (19 studies), the proportion of LBR was higher after the removal of septum (OR 49.58, 95% CI 29.93 to 82.13; p < 0.0001; moderate-heterogeneity) and the proportion of SA and PL was lower after the removal of septum, respectively (OR 0.02, 95% CI 0.02 to 0.04; p < 0.000; moderate-heterogeneity and OR 0.05, 95% CI 0.03 to 0.08; p = <0.000; low-heterogeneity).
Limitations, reasons for caution
The present meta-analysis is limited by the observational design of included studies because, in literature, there are no prospective randomized controlled trials (RCTs). In the second and third subgroup of analysis clinical heterogeneity within and between studies represents another limitation.
Wider implications of the findings
The results of this meta-analysis confirm the detrimental effect of uterine septum on PR, LBR, SA and PL. Its treatment seems to reduce the rate of SA. Metroplasty should still be considered as good clinical practice in patients with a history of infertility and recurrent abortion.
Trial registration number
Not applicable
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.
Collapse
Affiliation(s)
- G Spagnol
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - G Bonaldo
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - M Marchetti
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - A Vitagliano
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - A S Laganà
- University of Insubria, Department of Obstetrics and Gynecology- “Filippo Del Ponte” Hospital-, Varese, Italy
| | - M Scioscia
- Unit of Gynecological Surgery, Mater Dei Hospital, Bari, Italy
| | - A Andrisani
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - G Ambrosini
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - D D’Antona
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - A Riva
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - C Saccardi
- University of Padua, Department of Woman and Child Health, Padua, Italy
| | - M Noventa
- University of Padua, Department of Woman and Child Health, Padua, Italy
| |
Collapse
|
4
|
Noventa M, Riva A, Buzzaccarini G, Marin L, Sabbadin C, Bordin L, Menegazzo M, Ambrosini G, Andrisani A. P–680 Thyroid function in euthyroid women during controlled ovarian stimulation (COH): does the TSH fluctuations have an impact on IVF outcomes? Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
TSH blood levels play a role in terms of ovarian stimulation and pregnancy? Do we need to treat patients with TSH out of range?
Summary answer
Euthyroid patients with negative autoantibodies during COS should not be treated even if basal TSH is higher than 2.5 U/L
What is known already
Abnormal thyroid function is associated with adverse pregnancy outcomes, being essential during embryo implantation and early pregnancy. TSH receptors can be found in endometrial and ovarian tissues and during controlled ovarian stimulation TSH levels suffer modifications because of hyperestrogenemia. Subclinical hypothyroidism is defined as a TSH level greater than 4.5 mIU/L with normal FT4 levels. It is controversial whether or not to use first-trimester pregnancy and infertility thresholds for upper limit of 2.5 mIU/L TSH. However, neither American Thyroid Association nor the American Society Reproductive Medicine recommendations have clearly defined how infertile patients need to be treated.
Study design, size, duration
Between April 2016 and December 2019, we performed a retrospective observational study at the University Hospital of Padua, including patients who underwent IVF/ICSI treatments. We included patients with idiopathic or tubal infertility or with poor ovarian reserve, in presence of basal TSH≤ 4,5 U/L and negative anti-TPO Ab and anti-Tg Ab. Exclusion criteria were severe male factor, TSH<0,2 or > 4,5 U/L, BMI higher than 30, oncologic patients, uterine disease.
Participants/materials, setting, methods
We enrolled a total of 389 patients. We checked TSH blood levels on the day before starting stimulation (T0). We divided our patients according to TSH level < 2,5U/L (group A) or ≥ 2,5U/L (group B). We then checked TSH on the day of hCG trigger (ThCG). Delta TSH (ThCG-T0) was calculated and correlated to endometrial thickness, number of occytes retrieved, embryos obtained and frozen, Clinical Pregnancy Rate (CPR) and Live Birth Rate (LBR).
Main results and the role of chance
Group A (251) and group B (138) were homogeneous for age, body mass index, AMH levels, antral follicular count. Short ovarian stimulation cycle with GnRH antagonist and long cycle with GnRH agonist proportions were similar in both groups. Also, FSH recombinant and hMG gonadotropin use and total amount were similar for the two groups. No statistically significant difference was found between the groups in terms of endometrial thickness, follicles greater than 14 mm as medium diameter, number of oocytes retrieved, number of mature oocytes (MII), embryos obtained, number of embryos cryopreserved, CPR and LBR. However, when considering the Delta TSH, we found possible correlations in group A. In particular, the number of oocytes retrieved was higher in Delta TSH positive (3.4±2.2) rather than in Delta negative women (2.6±1.7) with a p value of 0.002. Moreover, mature oocytes (MII) were retrieved more frequently in Delta TSH positive (5.7±3.8) rather than in Delta negative women (4.5±3) with a p value of 0.008. Group B Delta TSH did not show any possible statistically significant correlations.
Limitations, reasons for caution
This is a retrospective study and results must be confirmed on a well-designed randomized controlled study. Moreover, since we use strict eligibility criteria, we enrolled few patients. Correlations must be considered with caution since the role of TSH is under study, especially when considering LBR outcome.
Wider implications of the findings: Our results are congruent with previous studies. In particular, we suggest not to treat patients with TSH levels on range (between 0.2mIU/L and 4.5 mIU/L). TSH increase during COS in euthyroid patients could be interpreted as a positive physiological response and it is associate with better COS outcomes.
Trial registration number
N/A
Collapse
Affiliation(s)
- M Noventa
- University of Padua, Department of Women and Children’s Health, padova, Italy
| | - A Riva
- University of Padua, Department of Women and Children’s Health, padova, Italy
| | - G Buzzaccarini
- University of Padua, Department of Women and Children’s Health, padova, Italy
| | - L Marin
- University of Padua, Department of Women and Children’s Health, padova, Italy
| | - C Sabbadin
- University of Padua, Department of Medicine DIMED-Endocrinology, padova, Italy
| | - L Bordin
- University of Padua, Department of Molecular Medicine-Biological Chemistry, padova, Italy
| | - M Menegazzo
- University of Padua, Andrology and Reproductive Medicine, padova, Italy
| | - G Ambrosini
- University of Padua, Department of Women and Children’s Health, padova, Italy
| | - A Andrisani
- University of Padua, Department of Women and Children’s Health, padova, Italy
| |
Collapse
|
5
|
Buzzaccarini G, Marin L, Noventa M, Vitagliano A, Riva A, Dessole F, Capobianco G, Bordin L, Andrisani A, Ambrosini G. Hyaluronic acid in vulvar and vaginal administration: evidence from a literature systematic review. Climacteric 2021; 24:560-571. [PMID: 33759670 DOI: 10.1080/13697137.2021.1898580] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Vulvovaginal pathology impairs the quality of life of both women in menopause and those who are not. Different therapies have been proposed, mainly related to estrogen therapy in postmenopausal women. However, some contraindications limit its use, and different moisturizers or lubricants have been tested. Hyaluronic acid is a promising and widely used vaginal medical treatment with a moisturizing action and appears to provide a solution. For this reason, we performed a systematic review of the literature. We searched for original articles without date restriction until 30 April 2020. We included all clinical trials which administered local hyaluronic acid in the vulva or vagina. Only English studies and those performed in humans were eligible. Seventeen original studies were included in the review (from randomized controlled trials to longitudinal studies). Hyaluronic acid was generally found to be effective in improving vulvovaginal symptoms (dyspareunia, itching, burning, dryness) and signs (bleeding, atrophy, vaginal pH). In conclusion, hyaluronic acid has the properties to be an efficient moisturizer for women suffering from vulvovaginal atrophy who have contraindications for estrogen therapy and for vulvovaginal signs and symptoms affecting sexual well-being. However, a well-designed randomized controlled trial is needed in order to clarify its efficacy and safety profile.
Collapse
Affiliation(s)
- G Buzzaccarini
- Gynaecologic and Obstetrics Clinic, Department of Women's and Children's Health, University of Padua, Padua, Italy
| | - L Marin
- Gynaecologic and Obstetrics Clinic, Department of Women's and Children's Health, University of Padua, Padua, Italy
| | - M Noventa
- Gynaecologic and Obstetrics Clinic, Department of Women's and Children's Health, University of Padua, Padua, Italy
| | - A Vitagliano
- Ospedale di Chioggia, ULSS 3 Serenissima, Chioggia, Italy
| | - A Riva
- Gynaecologic and Obstetrics Clinic, Department of Women's and Children's Health, University of Padua, Padua, Italy
| | - F Dessole
- Gynecologic and Obstetric Clinic, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
| | - G Capobianco
- Gynecologic and Obstetric Clinic, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
| | - L Bordin
- Department of Molecular Medicine - Biological Chemistry, University of Padova, Padova, Italy
| | - A Andrisani
- Gynaecologic and Obstetrics Clinic, Department of Women's and Children's Health, University of Padua, Padua, Italy
| | - G Ambrosini
- Gynaecologic and Obstetrics Clinic, Department of Women's and Children's Health, University of Padua, Padua, Italy
| |
Collapse
|
6
|
Trapp G, Hurworth M, Christian H, Bromberg M, Howard J, McStay C, Ambrosini G, Martin K, Harray A, Cross D, Oddy W, Hammond D. Prevalence and pattern of energy drink intake among Australian adolescents. J Hum Nutr Diet 2020; 34:300-304. [PMID: 32827226 DOI: 10.1111/jhn.12789] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 05/28/2020] [Accepted: 05/29/2020] [Indexed: 01/22/2023]
Abstract
BACKGROUND Energy drinks (ED) are popular among young people despite evidence of associated health risks. Research into the prevalence and pattern of ED intake among young people is sparse. The present study investigates the prevalence and pattern of ED intake among a large sample of adolescents, including how many consume them, how often, for what reasons and in what contexts. METHODS In 2018, all students in grades 7-12 attending 25 randomly selected Western Australian schools were invited to complete an online self-report survey about EDs. RESULTS Of the 3688 respondents, 51.2% reported consuming an ED. Of these 'ever consumers', 23.4% drank them monthly, 19.2% weekly and 2% every day. The average age of first intake was 10.7 years. One-fifth (19.7%) of 'ever consumers' reported consuming more than two EDs in 1 day. Reasons for ED use included taste, to boost energy levels, sport performance and studying. CONCLUSIONS The findings add to limited international evidence about adolescent ED use and provide valuable information to help ensure interventions to reduce intake address the underlying reasons and contexts of ED consumption.
Collapse
Affiliation(s)
- G Trapp
- Telethon Kids Institute, Perth Children's Hospital, Nedlands, WA, Australia.,School of Population and Global Health, The University of Western Australia, Nedlands, WA, Australia
| | - M Hurworth
- Telethon Kids Institute, Perth Children's Hospital, Nedlands, WA, Australia
| | - H Christian
- Telethon Kids Institute, Perth Children's Hospital, Nedlands, WA, Australia.,School of Population and Global Health, The University of Western Australia, Nedlands, WA, Australia
| | - M Bromberg
- The Law School, The University of Western Australia, Crawley, WA, Australia
| | - J Howard
- School of Law, The University of Notre Dame Australia, Fremantle, WA, Australia
| | - C McStay
- The Western Australian Department of Health, East Perth, WA, Australia
| | - G Ambrosini
- School of Population and Global Health, The University of Western Australia, Nedlands, WA, Australia.,The Western Australian Department of Health, East Perth, WA, Australia
| | - K Martin
- School of Population and Global Health, The University of Western Australia, Nedlands, WA, Australia
| | - A Harray
- School of Public Health, Curtin University, Bentley, WA, Australia
| | - D Cross
- Telethon Kids Institute, Perth Children's Hospital, Nedlands, WA, Australia.,School of Population and Global Health, The University of Western Australia, Nedlands, WA, Australia
| | - W Oddy
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
| | - D Hammond
- School of Public Health & Health Systems, University of Waterloo, Waterloo, ON, Canada
| |
Collapse
|
7
|
Virdis G, Dessole F, Andrisani A, Vitagliano A, Cappadona R, Capobianco G, Cosmi E, Ambrosini G, Dessole S. Cesarean scar pregnancy: a report of three cases and a critical review on the management. CLIN EXP OBSTET GYN 2019. [DOI: 10.12891/ceog5087.2019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
8
|
Delaneau O, Zazhytska M, Borel C, Giannuzzi G, Rey G, Howald C, Kumar S, Ongen H, Popadin K, Marbach D, Ambrosini G, Bielser D, Hacker D, Romano L, Ribaux P, Wiederkehr M, Falconnet E, Bucher P, Bergmann S, Antonarakis SE, Reymond A, Dermitzakis ET. Chromatin three-dimensional interactions mediate genetic effects on gene expression. Science 2019; 364:364/6439/eaat8266. [PMID: 31048460 DOI: 10.1126/science.aat8266] [Citation(s) in RCA: 108] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Accepted: 03/06/2019] [Indexed: 12/16/2022]
Abstract
Studying the genetic basis of gene expression and chromatin organization is key to characterizing the effect of genetic variability on the function and structure of the human genome. Here we unravel how genetic variation perturbs gene regulation using a dataset combining activity of regulatory elements, gene expression, and genetic variants across 317 individuals and two cell types. We show that variability in regulatory activity is structured at the intra- and interchromosomal levels within 12,583 cis-regulatory domains and 30 trans-regulatory hubs that highly reflect the local (that is, topologically associating domains) and global (that is, open and closed chromatin compartments) nuclear chromatin organization. These structures delimit cell type-specific regulatory networks that control gene expression and coexpression and mediate the genetic effects of cis- and trans-acting regulatory variants on genes.
Collapse
Affiliation(s)
- O Delaneau
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.,Swiss Institute of Bioinformatics (SIB), University of Geneva, Geneva, Switzerland.,Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland
| | - M Zazhytska
- Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - C Borel
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.,Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland
| | - G Giannuzzi
- Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - G Rey
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.,Swiss Institute of Bioinformatics (SIB), University of Geneva, Geneva, Switzerland.,Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland
| | - C Howald
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.,Swiss Institute of Bioinformatics (SIB), University of Geneva, Geneva, Switzerland.,Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland
| | - S Kumar
- Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.,Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - H Ongen
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.,Swiss Institute of Bioinformatics (SIB), University of Geneva, Geneva, Switzerland.,Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland
| | - K Popadin
- Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.,Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.,School of Life Science, Immanuel Kant Federal Baltic University, Kaliningrad, Russia
| | - D Marbach
- Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.,Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - G Ambrosini
- Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.,Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - D Bielser
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
| | - D Hacker
- Protein Expression Core Facility, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - L Romano
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
| | - P Ribaux
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
| | - M Wiederkehr
- Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - E Falconnet
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
| | - P Bucher
- Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.,Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - S Bergmann
- Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.,Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.,Computational Biology Division N1.05, Werner Beit North Faculty of Health Sciences, Cape Town, South Africa
| | - S E Antonarakis
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.,Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland
| | - A Reymond
- Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
| | - E T Dermitzakis
- Swiss Institute of Bioinformatics (SIB), University of Geneva, Geneva, Switzerland.,Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland.,Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.
| |
Collapse
|
9
|
Andrisani A, Marin L, Ragazzi E, Donà G, Bordin L, Dessole F, Armanini D, Esposito F, Vitagliano A, Sabbadin C, Ambrosini G. Is corifollitropin alfa effective in controlled ovarian stimulation among all poor ovarian responders? A retrospective comparative study. Gynecol Endocrinol 2019; 35:894-898. [PMID: 31081709 DOI: 10.1080/09513590.2019.1613360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
Several studies have compared the effectiveness of corifollitropin alfa versus daily gonadotropins in poor ovarian responders (PORs) undergoing controlled ovarian stimulation (COS), showing conflicting results in terms of IVF outcomes. Given the heterogeneity of patients included in the classification of POR according to 'Bologna criteria', the aim of this study was to evaluate the impact of corifollitropin alfa in two different categories of POR distinguished according to patients' antral follicle count (AFC). We retrospectively evaluated 104 infertile POR, split into two groups according to AFC (Group A ≤ 5; Group B > 5) and subgroups according to the ovarian stimulation regimen (corifollitropin alfa plus daily gonadotropins (Subgroup 1) versus daily gonadotropins alone (Subgroup 2)). Outcome measures were total oocytes, MII oocytes, total embryos, follicular output rate (FORT), implantation rate (IR), clinical pregnancy rate (CPR), miscarriage rate (MR), and live birth rate (LBR). Subgroup A1 experienced a lower number of total oocytes, MII oocytes, total embryos, and FORT (p < .05) in comparison to Subgroup A2, while no difference was found when comparing Subgroups B1 and B2. No difference was found between subgroups even in terms of IR, CPR, MR, and LBR. In conclusion, corifollitropin alfa may be as effective as daily gonadotropins in POR with AFC > 5 undergoing COS, while it might be inferior to daily gonadotropins in POR with AFC ≤ 5.
Collapse
Affiliation(s)
- A Andrisani
- Department of Women's and Children's Health, University of Padua, Salus Pueri, Padua, Italy
| | - L Marin
- Department of Women's and Children's Health, University of Padua, Salus Pueri, Padua, Italy
| | - E Ragazzi
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
| | - G Donà
- Department of Molecular Medicine, Biological Chemistry, University of Padua, Padua, Italy
| | - L Bordin
- Department of Molecular Medicine, Biological Chemistry, University of Padua, Padua, Italy
| | - F Dessole
- Department of Surgical, Microsurgical and Medical Sciences, Gynecologic and Obstetric Clinic, University of Sassari, Sassari, Italy
| | - D Armanini
- Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy
| | - F Esposito
- Department of Women's and Children's Health, University of Padua, Salus Pueri, Padua, Italy
| | - A Vitagliano
- Department of Women's and Children's Health, University of Padua, Salus Pueri, Padua, Italy
| | - C Sabbadin
- Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy
| | - G Ambrosini
- Department of Women's and Children's Health, University of Padua, Salus Pueri, Padua, Italy
| |
Collapse
|
10
|
Rothman J, Schwartz G, Surriga O, Ambrosini G. Suppression of KRAS-G12D and BRAF-V600E oncogene transcription with PNA-conjugates. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz238] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Andrisani A, Vitagliano A, Virdis G, Dessole F, Cappadona R, Marin L, Capobianco G, Dessole S, Ambrosini G. Accuracy of transvaginal ultrasound, saline infusion sonohysterography, and office hysteroscopy in the diagnosis of endometrial polyps. CLIN EXP OBSTET GYN 2019. [DOI: 10.12891/ceog5084.2019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
12
|
Andrisani A, Sabbadin C, Marin L, Ragazzi E, Dessole F, Armanini D, Donà G, Bordin L, Ambrosini G. The influence of thyroid autoimmunity on embryo quality in women undergoing assisted reproductive technology. Gynecol Endocrinol 2018; 34:752-755. [PMID: 29463152 DOI: 10.1080/09513590.2018.1442427] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The influence of thyroid autoimmunity in assisted reproductive technology (ART) outcome in euthyroid women is still controversial. In this study, we retrospectively evaluated embryo quality in 123 euthyroid women undergoing ART with or without thyroid autoantibodies (TAA). Embryo quality was assessed in 119 embryos of 29 infertile patients with TAA and in 394 embryos of 94 infertile patients without TAA. Our results showed not statistically significant differences in age, body mass index, anti-Müllerian hormone, follicle stimulating hormone, free triiodothyronine, and free thyroxine levels between cases and controls. Thyroid stimulating hormone was within the normal range, but significantly higher in TAA patients compared with the controls (2.4 ± 0.8 vs. 2 ± 0.9 mIU/L, respectively, p < .01). The number of oocytes picked up and fertilized was comparable between the two groups. Embryo quality was significantly impaired in women with at least one autoantibody (p < .001). Implantation rate, pregnancy rate, and ongoing pregnancy rate were comparable in the two groups. These results suggest a negative impact of thyroid autoimmunity in embryo quality in women undergoing ART even when thyroid function is normal.
Collapse
Affiliation(s)
- A Andrisani
- a Department of Women's and Children's Health , Salus Pueri, University of Padua , Padua , Italy
| | - C Sabbadin
- b Department of Medicine (DIMED), Endocrinology Unit , University of Padua , Padua , Italy
| | - L Marin
- a Department of Women's and Children's Health , Salus Pueri, University of Padua , Padua , Italy
| | - E Ragazzi
- c Department of Pharmaceutical and Pharmacological Sciences , University of Padua , Padua , Italy
| | - F Dessole
- d Department of Surgical, Microsurgical and Medical Sciences, Gynecologic and Obstetric Clinic , University of Sassari , Sassari , Italy
| | - D Armanini
- b Department of Medicine (DIMED), Endocrinology Unit , University of Padua , Padua , Italy
| | - G Donà
- e Department of Molecular Medicine , Biological Chemistry, University of Padua , Padua , Italy
| | - L Bordin
- e Department of Molecular Medicine , Biological Chemistry, University of Padua , Padua , Italy
| | - G Ambrosini
- a Department of Women's and Children's Health , Salus Pueri, University of Padua , Padua , Italy
| |
Collapse
|
13
|
Fossati R, Alexanian A, Liberati A, Marsoni S, Monferroni N, Nicolucci A, Parazzini F, Giganti M, Piffanelli A, Ghezzi P, Magnanini S, Rinaldini M, Berardi F, Di Biagio G, Testore F, Tavoni N, Palmieri D, Schittulli F, Pedicini T, Fumagalli M, Gritti G, Braga M, Marini G, Zamboni A, Cosentino D, Epifani C, Scognamiglio G, Perroni D, Peradotto F, Saba V, Indelli M, Santini A, Isa L, Scapaticci R, Aitini E, Gavazzini G, Smerieri F, Lomonaco I, Nascimben O, Locatelli E, Monti M, Ghislandi E, Gottardi O, Majno M, Poma C, Pluchinotta A, Armaroli L, Confalonieri C, Viola P, Sisto R, Buda F, Plaino R, Galletto L, Trolli B, Biasio M, Rolfo A, Vaudano G, Giolito M, Scoletta G, Ambrosini G, Busana L, Molteni M, Richetti A. Breast Cancer Estrogen and Progesterone Receptors: Associations with Patients' Clinical and Epidemiologic Characteristics. Tumori 2018; 77:472-8. [DOI: 10.1177/030089169107700605] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A total of 1095 patients with operable breast cancer and en-rolled in a randomized clinical trial were analysed for estrogen (ER) and progesterone (PgR) receptor content of their primary tumor, and the relationships between steroid receptor status and several epidemiologic characteristics were studied. The proportion of ER+ and median ER levels increased with age: compared to women younger than 40, those aged 66 or more were approximately three times more likely to have an ER+ tumor (OR = 3.0, 95% C.I. = 1.6–5.7). This difference tended to be more marked after comparison between patients with ER > 100 fmol/mg protein and ER- within the same age groups: OR = 7.04, 95 % C.I. = 2.89–17.12. No association emerged between age and PgR. ER status and concentrations were independent of menopausal status after adjustment for age, whereas the proportion of PgR+ and PgR levels were significantly lower in postmenopausal patients of the same age. The distribution of ER and PgR profiles was similar in relation to family history of breast cancer, reproductive events and other selected epidemiologic characteristics of the patients.
Collapse
Affiliation(s)
| | - R. Fossati
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A.A. Alexanian
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A. Liberati
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - S. Marsoni
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - N. Monferroni
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A. Nicolucci
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - F. Parazzini
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - M. Giganti
- Cattedra Medicina Nucleare, Istituto Radiologia, Università degli Studi di Ferrara
| | - A. Piffanelli
- Cattedra Medicina Nucleare, Istituto Radiologia, Università degli Studi di Ferrara
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rothman J, Surriga O, Ambrosini G, Vasudeva S, Schwartz G. Suppression of oncogene transcription - PNA as targeted cancer therapy for BRAF-V600E mutant melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Sabbadin C, Andrisani A, Zermiani M, Donà G, Bordin L, Ragazzi E, Boscaro M, Ambrosini G, Armanini D. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. J Endocrinol Invest 2016; 39:1015-21. [PMID: 27072668 DOI: 10.1007/s40618-016-0466-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Accepted: 04/02/2016] [Indexed: 10/22/2022]
Abstract
PURPOSE Spironolactone (SP) is an effective treatment for polycystic ovary syndrome (PCOS), but it is often associated with menstrual abnormalities whose mechanism is still under investigation. In this study, we investigated the serum sex steroids and endometrial thickness in 30 PCOS patients, before and after one-month 100 mg SP treatment. METHODS Serum FSH, LH, estradiol, progesterone and endometrial thickness were evaluated at the 14th and 16th day of the menstrual cycle, before and during short-term SP treatment. According to the presence (15 cases) or absence (15 cases) of menstrual bleeding at the 14th day during SP, the patients were divided into two groups, which were then compared using a two-tailed Student's t test. RESULTS Serum estradiol and endometrial thickness were lower than pretreatment at both determinations in all patients, but patients with bleeding had significantly lower estradiol values than non-bleeding ones, both before and after therapy. Endometrial thickness was significantly lower in the bleeding group compared with non-bleeding group only at the 16th day of the cycle. These differences were significant, even though the values of estradiol and endometrial thickness remained in the normal range. CONCLUSIONS SP therapy can reduce the values of estradiol and the endometrial thickness in patients with PCOS compared with pretreatment, but PCOS patients with bleeding had pretreatment estradiol values lower than the patients who did not complain of this side effect. Intermenstrual abnormalities may represent the low estrogen impregnation of endometrium due to SP, whose mechanism is complex, involving several factors, such as the effects of some metabolites of SP on estradiol and progesterone production, on their receptors, and the individual metabolism of SP in vivo.
Collapse
Affiliation(s)
- C Sabbadin
- Department of Medicine-Endocrinology, University of Padua, via Ospedale 105, 35128, Padua, Italy
| | - A Andrisani
- Department of Women's and Children's Health, University of Padua, via Giustiniani 3, 35128, Padua, Italy
| | - M Zermiani
- Department of Medicine-Endocrinology, University of Padua, via Ospedale 105, 35128, Padua, Italy
| | - G Donà
- Department of Molecular Medicine-Biological Chemistry, University of Padua, viale G. Colombo 3, 35131, Padua, Italy
| | - L Bordin
- Department of Molecular Medicine-Biological Chemistry, University of Padua, viale G. Colombo 3, 35131, Padua, Italy
| | - E Ragazzi
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, via Marzolo 5, 35131, Padua, Italy
| | - M Boscaro
- Department of Medicine-Endocrinology, University of Padua, via Ospedale 105, 35128, Padua, Italy
| | - G Ambrosini
- Department of Women's and Children's Health, University of Padua, via Giustiniani 3, 35128, Padua, Italy
| | - D Armanini
- Department of Medicine-Endocrinology, University of Padua, via Ospedale 105, 35128, Padua, Italy.
| |
Collapse
|
16
|
Virdis G, Gulotta A, Cherchi C, Spanedda G, Olzai MG, Ambrosini G, Dessole S, Capobianco G. Umbilical intra-abdominal vein varix: a case report and review of the literature. CLIN EXP OBSTET GYN 2016. [DOI: 10.12891/ceog3167.2016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
17
|
Virdis G, Dessole M, Dessole S, Ambrosini G, Cosmi E, Cherchi P, Capobianco G. Holt Oram syndrome: a case report and review of the literature. CLIN EXP OBSTET GYN 2016. [DOI: 10.12891/ceog3060.2016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
18
|
Virdis G, Gulotta A, Cherchi C, Spanedda G, Olzai MG, Ambrosini G, Dessole S, Capobianco G. Umbilical intra-abdominal vein varix: a case report and review of the literature. CLIN EXP OBSTET GYN 2016; 43:268-270. [PMID: 27132426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Fetal umbilical intra-abdominal vein varix (FIUV) is a rare congenital malformation characterized by focal dilatation of the umbilical vein. The authors report a case of pregnant woman at 32 weeks of gestation with a fetus affected by dilatation of an intra-abdominal portion of the umbilical vein. They performed continuous ultrasound and cardiotocographic monitoring, from admission to the delivery. They describe the case and perform a review of the literature.
Collapse
|
19
|
Virdis G, Dessole M, Dessole S, Ambrosini G, Cosmi E, Cherchil PL, Capobianco G. Holt Oram syndrome: a case report and review of the literature. CLIN EXP OBSTET GYN 2016; 43:137-139. [PMID: 27048037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Holt Oram syndrome is a rare autosomal dominant syndrome on average, of varying severity, which may result in heterogeneous pictures, predominantly with involvement of the bony segments of the upper limbs and the cardiovascular system. The syndrome is caused by mutations in two genes of the T-box (TBX5, 601 620 and TBX 3) located on the 12q24.1p. The authors report a case and review the literature.
Collapse
|
20
|
Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, Daniele B, Gaion F, Oliverio G, Duro M, Martignoni G, Pinna N, Sozzi P, Pancera G, Solina G, Pavia G, Pignata S, Johnson F, Labianca R, Apolone G, Zaniboni A, Monteforte M, Negri E, Torri V, Mosconi P, Fossati R. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol 2015; 27:274-80. [PMID: 26578734 DOI: 10.1093/annonc/mdv541] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 10/16/2015] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Colorectal cancer is the third most common and the third most lethal cancer in both men and women in developed countries. About 75% of cases are first diagnosed when the disease is classified as localized or regional, undergo potentially curative treatment and enter a post-treatment surveillance program. Although such programs drain significant resources from health systems, empirical evidence of their efficacy is scanty. PATIENTS AND METHODS Dukes B2-C colorectal cancer patients who had no evidence of disease at the end of their front-line treatment (surgery and adjuvant radiochemotherapy, if indicated) were eligible for the trial and randomized to two different surveillance programs. These programs differed greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments. Patients received baseline and yearly health-related quality-of-life (HR-QoL) questionnaires. Primary outcomes were overall survival (OS) and QoL. RESULTS From 1998 to 2006, 1228 assessable patients were randomized, 933 with colon cancer and 295 with rectal cancer. More than 90% of patients had the expected number of diagnostic procedures. Median follow-up duration was 62 months [interquartile range (IQR) 51-86] in the minimal surveillance group and 62 months (IQR 50-85) in the intensive group. At primary analysis, 250 patients had recurred and 218 had died. Intensive surveillance anticipated recurrence, as shown by a significant difference in mean disease-free survival of 5.9 months. Comparison of OS curves of the whole intention-to-treat population showed no statistically significant differences. HR-QoL of life scores did not differ between regimens. CONCLUSION Our findings support the conclusions of other randomized clinical trials, which show that early diagnosis of cancer recurrence is not associated with OS benefit. CLINICALTRIALSGOV NCT02409472.
Collapse
Affiliation(s)
- G Rosati
- Department of Oncology, Ospedale San Carlo, Potenza
| | - G Ambrosini
- Department of Oncology, Ospedale Santa Chiara, Trento
| | - S Barni
- Department of Oncology, Az. Osp. Treviglio-Caravaggio, Treviglio
| | - B Andreoni
- Department of Oncology, Istituto Europeo di Oncologia, Milan
| | - G Corradini
- Department of Oncology, Ospedale Civile, Rho
| | - G Luchena
- Department of Oncology, Ospedale Sant'Anna, Como
| | - B Daniele
- Department of Oncology, Az. Osp. G. Rummo, Benevento
| | - F Gaion
- Department of Oncology, Ospedale Civile, Camposampiero
| | - G Oliverio
- Department of Oncology, Ospedale Infermi, Rimini
| | - M Duro
- Department of Oncology, Ospedale Valduce, Como
| | - G Martignoni
- Department of Oncology, Ospedale S. Carlo Borromeo, Milan
| | - N Pinna
- Department of Oncology, Casa di Cura San Carlo, Paderno Dugnano
| | - P Sozzi
- Department of Oncology, Ospedale degli Infermi, Biella
| | - G Pancera
- Department of Oncology, Casa di Cura IGEA, Milan
| | - G Solina
- Department of Oncology, Az. Osp. Ospedali Riuniti Villa Sofia-Cervello, Palermo
| | - G Pavia
- Department of Oncology, Casa di Cura San Carlo, Paderno Dugnano
| | - S Pignata
- Department of Oncology, Istituto Nazionale dei Tumori, Napoli, Italy
| | - F Johnson
- Department of Surgery, St Louis University Hospital, St Louis, USA
| | - R Labianca
- Department of Oncology, Ospedali Riuniti, Bergamo
| | - G Apolone
- Department of Oncology, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia
| | - A Zaniboni
- Department of Oncology, Fondazione Poliambulanza, Brescia
| | - M Monteforte
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - E Negri
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - V Torri
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - P Mosconi
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - R Fossati
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | | |
Collapse
|
21
|
Pimpin L, Jebb S, Ambrosini G. Dairy protein in the post-weaning phase is positively associated with BMI and weight up to five years of age. Appetite 2015. [DOI: 10.1016/j.appet.2014.12.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
22
|
Ambrosini G, Johns D, Northstone K, Emmett P, Jebb S. Does a high sugar dietary pattern in childhood lead to increased adiposity in adolescence? Appetite 2015. [DOI: 10.1016/j.appet.2014.12.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
23
|
Rossi A, Vogrig E, Ganzitti L, Forzano L, Simoncini G, Romanello I, Ambrosini G, Marchesoni D. Prediction of large-for-gestation neonates with first-trimester maternal serum PAPP-A. Minerva Ginecol 2014; 66:443-447. [PMID: 24743523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The aim of this paper was to identify maternal/pregnancy characteristics, first trimester ultrasound parameters and biochemical indices which are significant independent predictors of large-for-gestational age (LGA) neonates. METHODS An Observational cross-sectional study was conducted at the Fetal Medicine Unit, Department of Obstetrics and Gynecology of the University of Udine (Italy). Seventy-two singleton pregnancies presenting for screening for chromosomal abnormalities by nuchal translucency and maternal serum biochemistry at 11-14 weeks. Linear regression was applied to develop first trimester prediction models for LGA. RESULTS Maternal height, parity, smoking, assisted conception and pregnancy-associated plasma protein-A were significant independent predictors of LGA. PAPP-A cut-off value expressed in MoM of 1.25 used for the study was chosen to obtain good sensitivity and specificity values. CONCLUSION Prediction for birthweight deviations (LGA) is feasible using data available at the routine 11-14 weeks' examination.
Collapse
Affiliation(s)
- A Rossi
- Department of Obstetrics and Gynecology, University of Udine, Udine, Italy -
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Capobianco G, Dessole M, Lutzoni R, Surico D, Ambrosini G, Dessole S. TVT-ABBREVO: efficacy and two years follow-up for the treatment of stress urinary incontinence. CLIN EXP OBSTET GYN 2014. [DOI: 10.12891/ceog19242014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
25
|
Rossi A, Forzano L, Romanello I, Ambrosini G, Iuri V, Marchesoni D. Comparison of pelvic masses score (PMS) and Risk of Malignancy Index (RMI 3) in the evaluation of pelvic masses. EUR J GYNAECOL ONCOL 2014; 35:421-424. [PMID: 25118484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE Ovarian cancer is the fourth cause of death from cancer in women worldwide and the majority of its diagnoses is made in an advanced stage of the disease. Several sonographic scoring systems have been created for a better preoperative discrimination between benign and malignant pelvic masses. The aim of this study was to evaluate the performances of the Risk of the Malignancy Index 3 (RMI 3) and the Pelvic Masses Score (PMS). MATERIALS AND METHODS This retrospective study was performed in 55 women admitted to the department of Obstetrics and Gynecology of University of Udine for surgical exploration of pelvic masses between 2009 and 2012. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for both the scores. RESULTS PMS showed a sensitivity of 100%, a specificity of 93.8%, a PPV of 70%, and a NPV of 100%, while RMI 3 yielded a sensitivity of 85%, a specificity of 91%, a PPV of 60%, and a NPV of 97.8%. CONCLUSION The authors found that, in discriminating between benign and malignant pelvic disease, the PMS method was more reliable than RMI3. PMS is a simple scoring system which can be used in clinical practice.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- CA-125 Antigen/blood
- Carcinoma, Endometrioid/blood
- Carcinoma, Endometrioid/diagnostic imaging
- Carcinoma, Endometrioid/pathology
- Cystadenocarcinoma, Serous/blood
- Cystadenocarcinoma, Serous/diagnostic imaging
- Cystadenocarcinoma, Serous/pathology
- Cystadenoma, Mucinous/blood
- Cystadenoma, Mucinous/diagnostic imaging
- Cystadenoma, Mucinous/pathology
- Cystadenoma, Serous/blood
- Cystadenoma, Serous/diagnostic imaging
- Cystadenoma, Serous/pathology
- Female
- Humans
- Membrane Proteins/blood
- Middle Aged
- Ovarian Cysts/blood
- Ovarian Cysts/diagnostic imaging
- Ovarian Cysts/pathology
- Ovarian Neoplasms/blood
- Ovarian Neoplasms/diagnostic imaging
- Ovarian Neoplasms/pathology
- Predictive Value of Tests
- ROC Curve
- Retrospective Studies
- Risk Assessment
- Sensitivity and Specificity
- Teratoma/blood
- Teratoma/diagnostic imaging
- Teratoma/pathology
- Ultrasonography
- Young Adult
Collapse
|
26
|
Capobianco G, Simbula L, Soro D, Meloni F, Cossu-Rocca P, Dessole S, Ambrosini G, Cherchi PL, Meloni GB. Management of breast lobular carcinoma in situ: radio-pathological correlation, clinical implications, and follow-up. EUR J GYNAECOL ONCOL 2014; 35:157-162. [PMID: 24772919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE OF INVESTIGATION To show management of patients with breast lobular carcinoma in situ (LCIS). MATERIALS AND METHODS This study is the retrospective review of 65 patients, between 1996 and 2012, with isolated LCIS of the breast, evaluated through clinical examination, ultrasound, and mammography at the first examination and follow-up. RESULTS In 53 patients (81.54%), clinical examination was negative. In 14/65 (21.54%) cases, ultrasound was positive and led to biopsy. The clusters of tiny calcifications were the predominant mammographic pattern (45 cases, 69.23%). Forty-six patients (70.77%) underwent surgical biopsy after guided stereotactic placement of metallic marker (hook-wire), 12 (18.46%) by stereotactic vacuum biopsy (SVB), 5 (7.69%) by core needle biopsy (CNB) under ultrasound guidance, two (3.08%) patients CNB with clinically palpable nodules. Fourteen (21.54%) women underwent a quadrantectomy or total mastectomy after the first diagnosis; in this latter group follow-up was negative. Among the 51 patients (78.46%) who did not undergo quadrantectomy or total mastectomy, five relapses occurred, respectively, three LCIS and two infiltrating ductal carcinomas (IDC). Follow-up ranged from 12 to 144 months. CONCLUSION LCIS is a risk factor for invasive carcinoma and should be managed with careful follow-up, but if there is a discrepancy between pathology and imaging, surgical excision is mandatory.
Collapse
|
27
|
Capobianco G, Dessole M, Lutzoni R, Surico D, Ambrosini G, Dessole S. TVT-ABBREVO: efficacy and two years follow-up for the treatment of stress urinary incontinence. CLIN EXP OBSTET GYN 2014; 41:445-447. [PMID: 25134295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE To assess the effectiveness of inside-out TVT-ABBREVO in the surgical treatment of female stress urinary incontinence (SUI) with mean two-year follow-up. MATERIALS AND METHODS Fifty-six women underwent surgery for moderate-severe SUI. The technology used was the TVT-ABBREVO inside-out. Each woman at 12 and 24 months underwent postoperative evaluation by means of urodynamics, Q-tip test, CST, transperineal ultrasonography, and administration of "King's Health Questionnaire" (KHQ). RESULTS The mean age of the women was 57.03 +/- 11.1 years (range 42-75). Postoperative urodynamics (12 months follow-up) resulted to be normal in 43/56 patients (76.79%), in 10/56 (17.86%) cases resulted in a considerable improvement of the symptomatology, and only 1/56 (1.78%) case had de novo overactive bladder (OAB), in 2/56 (3.57%) symptomatology unchanged. After administration of the KHQ 43/56 cases (76.79%) had resolution of the symptomatology, 10/56 cases (17.86%) improvement of the symptomatology, and no change in 3/56 cases (5.36%). CONCLUSION In the authors' experience, the TVT-ABBREVO resulted technically simple. The TVT-ABBREVO procedure provides high objective and subjective long-term efficacy, a clinically meaningful improvement in patient quality of life, and an excellent safety profile.
Collapse
|
28
|
Capobianco G, Marras V, Wenger JM, Santeufemia DA, Ambrosini G, Lutzoni R, Dessole M, Cherchi PL. P16 immunostaining and HPV testing in histological specimens from the uterine cervix. EUR J GYNAECOL ONCOL 2013; 34:227-230. [PMID: 23967551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND The cellular tumor suppressor protein pl61NK4a (p16) has been identified as a biomarker for transforming human papilloma virus (HPV) infections. P16 is a cyclin-dependent kinase inhibitor that regulates the cell cycle and cell proliferation by inhibiting cell cycle G1 progression. PURPOSE OF THE STUDY To confirm the role of p16 as biomarker for transforming HPV infections and possible clinical applications in histological samples from the uterine cervix. MATERIALS AND METHODS The subject of this study included 56 biopsies of the cervical canal collected from January 2012 to September 2012 in the Institute of Pathology of the University of Sassari. The search for HPV immunohistochemistry was performed with the monoclonal antibody DAKO 1:25, while for the detection of p16 was used CINtecTM p16 (INK4a) histology kit. RESULTS In 56 biopsies performed in women aged between 23 and 69 years, the authors highlighted, by histological analysis, 24 cases of low-grade squamous intraepithelial lesion (LSIL) - cervical intraepithelial neoplasia (CIN1) and 31 cases of high-grade squamous intraepithelial lesion (HSIL) - CIN2/3); 15 CIN2, 14 CIN3, and two cervical squamous cell carcinoma in situ (SCIS). One case was an infiltrating squamous cell carcinoma (ISC). In 24 CIN1, there was a 16.67% positivity for p16 and an equal percentage occurred for HPV. In 15 cases of CIN2 the percentage of positivity for p16 was considerably increased (73.33%), unlike the search for HPV which had a positivity rate of 20%. Finally, in 14 cases of CIN3, and in three carcinomas, the positivity for p16 was equal to 100%, however the search for HPV positivity was between 0% and 7.14%. CONCLUSIONS These results demonstrated that p16 was a highly sensitive marker of cervical dysplasia. The authors have shown that p16 overexpression increased with the severity of cytological abnormalities and that had a greater ability to identify the viral infection compared to the classical immunohistochemical staining for HPV.
Collapse
Affiliation(s)
- G Capobianco
- Gynaecologic and Obstetric Clinic, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Capobianco G, Wenger JM, Marras V, Cosmi E, Ambrosini G, Dessole M, Cherchi PL. Immunohistochemical evaluation of epithelial antigen Ber-Ep4 and CD10: new markers for endometriosis? EUR J GYNAECOL ONCOL 2013; 34:254-256. [PMID: 23967557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Early and certain diagnoses of endometriosis are mandatory to begin the correct treatment and to exclude the risk of endometriosis-associated ovarian carcinoma (EOC) and endometrial stromal sarcoma (ESS). PURPOSE OF THE STUDY To assess the immunohistochemical expression of Ber-Ep4, an epithelial antigen, and CD10 in endometriosis. MATERIALS AND METHODS Forty-eight women underwent laparoscopic surgery for endometriosis and endometriotic samples were recovered for histology. In all surgical specimens Ber-Ep4 and CD10 were searched by an immnohistochemical method. The authors evaluated the correlations among the immunohistochemical positivity and the location of endometriosis. RESULTS Most cases (40/48 83.34%) were represented by ovarian endometriotic cyst. Among the eight remaining cases, three (3/48, 6.25%) were pelvic endometriotic lesions, two (2/48, 4.17%) peritoneum of vesico-uterine pouch, one vaginal lesion (2.08%), one salpinx lesion (2.08%), and one inguinal location (2.08%). Ber-Ep4 and CD10 were expressed in 90% and in 100% of the ovarian lesions, respectively. In pelvic lesions Ber-Ep4 and CD10 showed both 66.67% of positivity and had the same pattern in peritoneal, salpinx, vaginal, and inguinal lesions (50%, 100%, 100%, 100%, respectively). Ber-Ep4 was negative in 6/48 (12.5%) cases whereas CDO10 was negative in 2/48 (4.17%) cases of endometriosis. The sensitivity of Ber-Ep4 and CD10 for endometriosis diagnosis were 87.50% and 95.83%, respectively. Immunohistochemistry for Ber-Ep4 showed positivity in all cases of endometriosis with typical cubic epithelium, whereas CD10 was positive in 1/2 (50%) atypical case. CONCLUSION Immunohistochemical expression of Ber-Ep4 and CD10 was positive in most cases of endometriosis and was useful in differential diagnosis with mesothelial cysts. Ber-Ep4 was negative in cases of hyperplastic epithelium or cytological atypia; these cases are not well-differentiated and could be optimally treated by surgery and not by hormonal therapy because of the risk of cancer degeneration.
Collapse
Affiliation(s)
- G Capobianco
- Gynaecologic and Obstetric Clinic, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
| | | | | | | | | | | | | |
Collapse
|
30
|
Ahern A, Palla L, Ambrosini G, Caterson I, Hauner H, Jebb S. Changes in eating behaviour traits during weight loss and their relationship to changes in diet and body weight. Appetite 2012. [DOI: 10.1016/j.appet.2012.05.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Zuccarello D, Ferlin A, Garolla A, Menegazzo M, Perilli L, Ambrosini G, Foresta C. How the human spermatozoa sense the oocyte: a new role of SDF1-CXCR4 signalling. ACTA ACUST UNITED AC 2011; 34:e554-65. [DOI: 10.1111/j.1365-2605.2011.01158.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Andrisani A, Serena A, Ambrosini G, Capobianco G, Chiarelli S. Proximal-type epithelioid sarcoma of the mons pubis: report of a case. EUR J GYNAECOL ONCOL 2011; 32:339-342. [PMID: 21797131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
INTRODUCTION Proximal-type epithelioid sarcoma (PES) represents an extremely rare and aggressive form of soft tissue neoplasm, typically presenting as a painless subcutaneous nodule in the trunk often located in the genital area. CASE REPORT A 46-year-old female was subjected to the excision of a growing soft tissue mass in the mons pubis that, at histology, was identified as PES. The tumor showed an extreme aggressiveness involving subsequently adjoining structures and lymph nodes despite subsequent wide surgical resections during the following months. DISCUSSION Gynecologists should pay careful attention to all soft tissue masses of the perineal area or external genitalia. It is important to know the possible genital localization of PES which, although rare, is an aggressive high-grade soft tissue tumor with a deceitful behavior, poorly sensitive to chemotherapy and radiotherapy. Surgery, though wide and demolitive, often fails to obtain the necessary radicality.
Collapse
Affiliation(s)
- A Andrisani
- Department of Gynecological Science and Reproductive Medicine, University of Padova, Padova, Italy.
| | | | | | | | | |
Collapse
|
33
|
Donà G, Fiore C, Tibaldi E, Frezzato F, Andrisani A, Ambrosini G, Fiorentin D, Armanini D, Bordin L, Clari G. Endogenous reactive oxygen species content and modulation of tyrosine phosphorylation during sperm capacitation. ACTA ACUST UNITED AC 2010; 34:411-9. [PMID: 20738429 DOI: 10.1111/j.1365-2605.2010.01097.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Generation of controlled amounts of reactive oxygen species (ROS) and phosphorylation of protein tyrosine (Tyr) residues are two main cellular changes involved in sperm capacitation. This study examined the relationship between tyrosine-phosphorylation (Tyr-P) and endogenous ROS production during sperm capacitation, and correlated them with both sperm motility and functionality expressed as acrosome-reacted cells. Immediate ROS generation was observed to peak after a 45-min incubation, followed by a rapid decrease in ROS content and successive regeneration of the ROS peak in 3 h and later. These two peaks were directly correlated with both the Tyr-P process involving sperm heads and tails, and the acrosome reaction (69 ± 8% and 65 ± 4%, respectively). The period of low-ROS content resulted in low Tyr-P patterns, located exclusively in the cell midpiece, and drastic reduction in acrosome-reacted cells. Ascorbic acid addition inhibited both Tyr-P patterns and acrosome reactions, whereas NADPH induced high ROS generation, with Tyr-P patterns located only on sperm tails, and prevented the acrosome reaction. Sperm hyperactivation was insensitive to ROS content. This is an important parameter for evaluation of sperm capacitation, which is achieved only when both ROS generation reaches a peak and Tyr-P involves the sperm head.
Collapse
Affiliation(s)
- G Donà
- Department of Biological Chemistry Endocrinology Unit, University of Padova, Padova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Soini B, Frisinghelli M, Ambrosini G, Caffo O, Caldara A, Ferro A, Murgia V, Valduga F, Galligioni E. Paclitaxel, 5-fluorouracil, and cisplatin (PFC) combination in patients (pts) with localized or advanced gastric-gastroesophageal junction adenocarcinoma (G-GEJA): A monoistitutional experience. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Soini B, Caffo O, Ferro A, Ambrosini G, Murgia V, Valduga F, Caldara A, Eccher C, Tumulo S, Galligioni E. Individual risk factors for venous thromboembolism (VTE) in cancer patients treated with targeted therapies (TT). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20549 Background: Many anticancer drugs, alone or in combination, can significantly increase the risk of VTE in cancer patients. Vascular complications however, including VTE, have emerged as a relevant toxicity also with targeted therapies (TT) (Elice, Am. J. Hematol.2008). Recently, a simple model for predicting risk of VTE in cancer patients receiving chemotherapy (CT) has been developed, based on a number of clinical and laboratory variables (Khorana, Blood 2008). In this report, we have evaluated the incidence of VTE and assessed the predictive value of the Khorana's model, in cancer patients receiving TT, alone or combined with CT. Methods: From a consecutive series of 278 patients, treated with TT ± CT between January 2006 and August 2008, we have identified for each patient the baseline values, before TT treatment, of the following variables: age, performance status, primary site of cancer, stage, comorbidities, body mass index, hemoglobin, leukocyte and platelet count and use of erythropoiesis stimulating agents. All variables have been correlated with the occurrence of VTE, at the uni- and multivariate analysis. Results: TT treatment consisted of trastuzumab in 103 patients (37%), bevacizumab in 69 (25%), cetuximab in 29 (10%), rituximab in 41 (15%), sunitinib in 16 (6%), erlotinib in 12 (4%) and sorafenib in 8 (3%). In 163 patients (59%) TT were administered concurrently with CT. In a period of 2–360 days (median 125), 14 patients (5%) developed deep vein thrombosis, complicated by pulmonary embolism in 5. None of the variables of Khorana's model has shown any significant value, in predicting VTE risk, as well as any association with different TT (i.e. bevacizumab or sunitinib) or the concomitant administration of CT. Conclusions: In our experience, the Khorana's model does not appear able to predict the risk of VTE, in patiens receiving TT treatments. Other models may be required for identifying high risk patients, who would benefit from a prophylaxis of thrombotic events. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Soini
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - O. Caffo
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - A. Ferro
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - G. Ambrosini
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - V. Murgia
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - F. Valduga
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - A. Caldara
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - C. Eccher
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - S. Tumulo
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| | - E. Galligioni
- S. Chiara Hospital, Trento, Italy; Fondazione Bruno Kessler, Trento, Italy; S. Maria degli Angeli Hospital, Pordenone, Italy
| |
Collapse
|
36
|
Galligioni E, Berloffa F, Caffo O, Tonazzolli G, Ambrosini G, Valduga F, Eccher C, Ferro A, Forti S. Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. Ann Oncol 2008; 20:349-52. [PMID: 18718889 DOI: 10.1093/annonc/mdn567] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND We describe our experience with an electronic oncological patient record (EOPR) for the total management of cancer patients. METHODS The web-based EOPR was developed on the basis of a user-centred design including user education and training, followed by continuous assistance; user acceptance was monitored by means of three questionnaires administered after 2 weeks, 6 months and 6 years. RESULTS The EOPR has been used daily for all in-ward, day hospital and ambulatory clinical activities since July 2000. The most widely appreciated functions are its rapid multipoint access, the self-updated summary of the patients' clinical course, the management of the entire therapeutic programme synchronised with working agendas and oncological teleconsultation. Security and privacy are assured by means of the separate storage of clinical and demographic data, with access protected by login and a password. The questionnaires highlighted appreciation of rapid data retrieval and exchange and the perception of improved quality of care, but also revealed a sense of additional work and a negative impact on doctor-patient relationships. CONCLUSIONS Our EOPR has proved to be effective in the total management of cancer patients. Its user-centred design and flexible web technology have been key factors in its successful implementation and daily use.
Collapse
Affiliation(s)
- E Galligioni
- Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Caffo O, Murgia V, Ambrosini G, Brugnara S, Caldara A, Ferro A, Frisinghelli M, Soini B, Valduga F, Galligioni E. Gemcitabine (G) and cisplatin (C) in a modified 3-week schedule for non-small cell lung cancer (NSCLC): Impact on hematologic toxicity and dose intensity (DI). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Ambrosini G, Gierend M, Grasedyck K, Lemmel E, Raspe H, Reiter W, Schneider H, Sörensen H, Zeidler H. Der Einfluß von Alter und Komorbidität auf die Inzidenz von unerwünschten Wirkungen unter Piroxicam. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047973] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Porcu E, Venturoli S, Damiano G, Ciotti PM, Notarangelo L, Paradisi R, Moscarini M, Ambrosini G. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online 2008; 17:265-7. [DOI: 10.1016/s1472-6483(10)60204-0] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
40
|
Ferro A, Triolo R, Caffo O, Barbareschi M, Leonardi E, Frisinghelli M, Caldara A, Ambrosini G, Lucenti A, Galligioni E. Retrospective analysis of clinico-pathological features and outcomes of 2,686 hormone receptors-positive breast cancer (HR+) patients in a consecutive mono-institutional series. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11036 Background: Clinico-pathological patterns, management and outcomes of HR+ vs HR- have been evaluated in a retrospective study. Methods: A series of 2686 BC patients (pts), treated at our institution from 1988 to 2000 with known immunohistochemical receptor status was investigated. Correlation between HR status and tumour size (T), nodal status (N), grading (G), mib-1, HER-2 and p53 and was evaluated by χ square test. Statistical analysis was performed to test the interaction between HR status and Disease Free Survival (DFS) and with specific and overall survival, using the log-rank test. Results: Among 2686 patients, 467 HR- (17%) and 2219 (83%) HR+ (364 pre and 1855 postmenopausal) were observed, with 1586 ER+PgR+, 555 ER+PgR-, 78 ER-PgR+. Pts with positive HR status showed a statistically significant correlation with lower T, G, mib-1, HER-2 and p53 expression.Chemotherapy was administered to 681 HR+BC (31% ) and to 301 HR-BC (65%), according to stage, age, and G. Tamoxifen based endocrine therapy was administered to 1167 HR+BC (53%) (associated to chemotherapy in 428 and alone in 739 pts). At a median follow up of 108 months, 499 relapses occurred in HR+ (22%) , and 141 in HR- pts (30%), with a 5,10, 15y DFS of 83%,72%, 62% in HR+ and 72%,66%, 57% respectively in HR- pts. More frequent sites of relapse were soft tissue (46%) and bone (35%) in HR+ and soft tissue (50%) and visceral (30%) in HR- pts. Seven hundred sixty pts have died: 576 HR+ (26%) and 184 HR- (39%), with a 5, 10, 15y specific survival of 90%, 84%, 75% which was significantly superior to the 78%, 73%, 69% respectively of HR-. However, considering that 230 HR+ and 44 HR- pts died without relapse, the 5,10,15y overall survival was 90%, 75% 61% for HR+ and 78%, 67%, 60% respectively for HR-. It appears therefore that the specific survival advantage in early years in favour of HR+ is progressively reduced by non specific mortality in late years which results in similar 15 y OS rates among HR+ and HR- pts. Conclusions: Our series appear to confirm the relationship between HR+ status and other more favourable clinical-pathological features, although long term OS is not apparently affected. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Ferro
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - R. Triolo
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - O. Caffo
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - M. Barbareschi
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - E. Leonardi
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - M. Frisinghelli
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - A. Caldara
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - G. Ambrosini
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - A. Lucenti
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| | - E. Galligioni
- Santa Chiara Hospital, Trento, Italy; Ragusa Hospital, Ragusa, Italy; St. Chiara Hospital, Trento, Italy
| |
Collapse
|
41
|
Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2006; 26:3473-81. [PMID: 17146434 DOI: 10.1038/sj.onc.1210136] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53-/- cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wild-type E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73alpha and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1-dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.
Collapse
Affiliation(s)
- G Ambrosini
- Laboratory of New Drug Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | |
Collapse
|
42
|
Kocinaj D, Cioppa A, Ambrosini G, Tesorio T, Salemme L, Sorropago G, Rubino P, Picano E. Radiation dose exposure during cardiac and peripheral arteries catheterisation. Int J Cardiol 2006; 113:283-4. [PMID: 16330116 DOI: 10.1016/j.ijcard.2005.09.035] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2005] [Accepted: 09/20/2005] [Indexed: 11/21/2022]
Abstract
BACKGROUND Ionising radiation carries an oncogenic risk which is linearly related to the dose. An estimation of the effective dose can be obtained from the measurements of the dose-area product (DAP), which is a measure of stochastic risk and a potential quality indicator. AIM To assess radiation exposure of patients in a large volume cardiac cath-lab. METHODS A retrospective analysis of adult cardiac and peripheral percutaneous procedures (April to December 2004) was carried out to determine the DAP and estimated risk of malignancy. We identified 6 groups: Group 1 (n=100, coronary angiography and ventriculography); Group 2 (n=50, carotid stenting); Group 3 (n=50, aortography+coronary angiography+ventriculography); Group 4 (n=100, inferior extremities angiography+predilatation and stenting); Group 5 (n=100, coronary angiography+ventriculography+direct coronary stenting); Group 6 (n=100, coronary angiography+ventriculography+coronary predilation and stenting). Dose-area product meter attached on the X-ray unit was used for the estimation of the radiation dose received by the patient during the procedures. RESULTS DAP values (mean+/-S.D.) ranged from 41+/-30 Gy cm2 in Group 1 (lowest) to 118+/-89 Gy cm2 in Group 6 (highest). Within each group, individual radiation exposure varies substantially: from 11 to 200 Gy cm2 in Group 1, and from 30 to 733 Gy cm2 in Group 6 patients. Average exposure in a Group 6 patient corresponds to a risk of mortality from a malignancy of about 1 in 1000. CONCLUSION The radiation dose varies substantially across different types of procedures and up to tenfold within the same procedure. The enhanced knowledge of radiation dose might help the cardiologist to implement radiation sparing procedures eventually minimizing patient and operator radiation hazards in invasive cardiology.
Collapse
|
43
|
Alfonso H, de Klerk N, Reid A, Ambrosini G, Olsen N, Beilby J, Musk B. 6 Vitamin A and cancer prevention in workers previously exposed to asbestos in Wittenoom. Lung Cancer 2006. [DOI: 10.1016/s0169-5002(07)70082-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
de Klerk N, Alfonso H, Reid A, Ambrosini G, Olsen N, Berry G, Musk B, Palmer L. 2 Familial clustering of mesothelioma in subjects exposed to crocidolite at Wittenoom. Lung Cancer 2006. [DOI: 10.1016/s0169-5002(07)70078-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Alfonso H, de Klerk N, Reid A, Ambrosini G, Olsen N, Beilby J, Musk B. 149 Effects of long-term supplementation with retinol on plasma, malignant mesothelioma, lung cancer and potential side-effects in the Wittenoom cohort. Lung Cancer 2006. [DOI: 10.1016/s0169-5002(07)70225-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Galligioni E, Triolo R, Lucenti A, Ferro A, Frisinghelli M, Ambrosini G, Murgia V, Micciolo R. Clinical presentation and outcomes of 2,924 early breast cancer patients (br.ca. pts) treated in a single institution in a 10-year period with a long follow up. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10669 Background: A consecutive series of br.ca. pts, treated between Jan 1st 1990 to Dec 31st 1999 in our Department, is the basis of our retrospective study, aimed to create a data base on routinary clinical management of early br.ca. pts, to which compare similar series and literature data. Methods: All Clinical Records were reviewed and computerized. Disease free and overall survival were estimated using the product-limit method of Kaplan and Meier. The log-rank test was used to compare prognosis between different subgroups. Results: Among 2924 consecutive br.ca. pts, 836 were younger than 50 years (med. age 44) and 2088 older (med. age 63). Regional nodes were negative (N−) in 1754, positive (N+) in 1027 and unknown in the remaining pts. So, 2593 pts were stage I-II and 301 stage IIIA-B. Hormonal Receptor status (available on 2560 pts) was positive for Estrogen (ER+) in 2021 pts and for Progesterone (PgR+) in 1649 pts. Moreover, 1571 pts were ER+Pgr+, 539 ER-PgR−, 78 ER-PgR+ and 461 ER+PgR−. HER2 was overexpressed in 262/1426 (18%) pts. Tumor grading (available on 2176 cases) was G1–2 in 1411 and G3–4 in 765 cases. After surgery, 731 pts received adjuvant Tamoxifen, 507 pts CMF ± Antracyclines chemotherapy, 434 pts both chemotherapy and Tamoxifen and 958 pts none. (no therapy data are available for the remaining 334 pts). At a median f.up of 9.8 years, 993/2924 pts (33.9%) have recurred, (med. DFS 137 mos) with a 5, 10 and 15 y probability of recurrence of 26, 44 and 63% respectively. Corresponding figures of recurrence for N− pts were 14, 30 and 50% (med. DFS 168 mos), while for N+ pts were 41, 61 and 77% (med DFS 81 mos). For younger N+ pts treated with chemotherapy, the 5 years probability of recurrence was 34% while it was 24% for older ER+ pts treated with hormonal therapy. So far, 794/2924 (27.5%) pts have died, with a 5, 10 and 15 y probability of death of 13, 27 and 41%. This was 5, 16 and 28% for N- pts and 22, 41 and 56% for N+ pts. For younger N+ pts treated with chemotherapy, the 5 y probability of death was 14%, as it was for older ER+ pts treated with Tamoxifen. Conclusions: Although this data are not yet conclusive, it appears that large part of the clinical improvements reported in clinical trials may be achieved in the routine management of breast cancer pts. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Galligioni
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| | - R. Triolo
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| | - A. Lucenti
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| | - A. Ferro
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| | - M. Frisinghelli
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| | - G. Ambrosini
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| | - V. Murgia
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| | - R. Micciolo
- St. Chiara Hospital, Trento, Italy; University of Trento, Trento, Italy
| |
Collapse
|
47
|
Ambrosini G, Andrisani A, Porcu E, Rebellato E, Revelli A, Caserta D, Cosmi E, Marci R, Moscarini M. Oocytes cryopreservation: state of art. Reprod Toxicol 2006; 22:250-62. [PMID: 16787736 DOI: 10.1016/j.reprotox.2006.04.024] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2006] [Revised: 04/26/2006] [Accepted: 04/27/2006] [Indexed: 11/16/2022]
Abstract
In the present review article we sought to analyze, on the basis of a systematic review, the indications, rationale of oocytes cryopreservation, as well as the techniques that improved the aforementioned procedure in order to higher the pregnancy rate in women undergoing that procedure. Moreover, we pointed out the importance of oocytes cryopreservation in the research field as oocyte banking may be of utmost importance to increase the availability of oocytes for research applications such as genetic engineering or embryo cloning. Oocyte freezing has 25 year of history alternating successes and setbacks. Human oocytes have a delicate architecture but are freezable. Clinical efficiency remains low, but healthy children have been born, indicating that chromosomally normal embryos can originate from frozen oocytes. Freezing protocols are not yet optimal and it is now desirable to combine empirical and theoretical knowledge.
Collapse
Affiliation(s)
- G Ambrosini
- Department of Gynecological Science and Reproductive Medicine, University of Padua School of Medicine, Padua, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Wilson AS, Goodall JE, Ambrosini G, Carruthers DM, Chan H, Ong SG, Gordon C, Young SP. Development of an interactive learning tool for teaching rheumatology—a simulated clinical case studies program*. Rheumatology (Oxford) 2006; 45:1158-61. [PMID: 16531436 DOI: 10.1093/rheumatology/kel077] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES To promote independent self-study involving problem solving and decision analysis in the undergraduate medical curriculum, we have developed a series of interactive web-based clinical case studies. METHODS An initial needs assessment was performed to determine students' attitudes to e-learning. From these results we designed a series of 30 interactive case studies for delivery from a web-server. RESULTS A survey of 59 undergraduate students believed that online teaching resources were a useful supplement to existing teaching and they could see a positive use for e-learning. The interactive case studies program was well received by a broad range of respondents (n = 84) of different abilities and backgrounds who felt that the program was realistic and clearly presented in an intuitive manner. CONCLUSIONS The recent increases in numbers of medical undergraduates, the trend towards student-centred learning and the emphasis on patient-related teaching means a great pressure on teachers and resources in medical schools. The case studies program we have developed was effective and well received by both biomedical and medical students. This approach may provide a way to increase the exposure of students to clinical cases involving interactive diagnostic and treatment procedures, that mimic real-world scenarios, but with fewer resource implications.
Collapse
Affiliation(s)
- A S Wilson
- Department of Rheumatology, Division of Immunity and Infection, School of Medicine, University of Birmingham, Edgbaston, Birmingham, UK
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Reid A, de Klerk N, Ambrosini G, Olsen N, Pang SC, Musk AW. The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. Occup Environ Med 2005; 62:665-9. [PMID: 16169910 PMCID: PMC1740875 DOI: 10.1136/oem.2004.018531] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIMS To examine the hypothesis that people with benign pleural disease or asbestosis have an increased risk of malignant mesothelioma beyond that attributable to their degree of asbestos exposure. METHODS Former workers and residents of the crocidolite mining and milling town of Wittenoom are participating in a cancer prevention programme (n = 1988). The first plain chest radiograph taken at the time of recruitment into the cancer prevention programme was read for evidence of benign pleural disease and asbestosis, using the UICC classification. Crocidolite exposure of former workers was derived from employment records and records of dust measurements performed during the operation of the asbestos mine and mill between 1943 and 1966. Based on fibre counts, exposure for former residents was determined using duration of residence and period of residence (before and after a new mill was commissioned in 1957) and interpolation from periodic hygienic measures undertaken from personal monitors between 1966 and 1992. Cox proportional hazards modelling was used to relate benign pleural disease, asbestosis, asbestos exposure, and mesothelioma. RESULTS Between 1990 and 2002, there were 76 cases of mesothelioma (56 of the pleura and 20 of the peritoneum). Cases had more radiographic evidence of (all) benign pleural disease, pleural thickening, blunt/obliterated costophrenic angle, and asbestosis than non-cases. Adjusting for time since first exposure (log years), cumulative exposure (log f/ml-years), and age at the start of the programme, pleural thickening (OR = 3.1, 95% CI 1.2 to 7.6) and asbestosis (OR = 3.3, 95% CI 1.3 to 8.6) were associated with an increased risk of peritoneal mesothelioma. There was no increased risk for pleural mesothelioma. CONCLUSION The presence of benign pleural disease, in particular pleural thickening, and asbestosis appears to increase the risk of mesothelioma of the peritoneum, but not of the pleura beyond that attributable to indices of asbestos exposure in this cohort of subjects exposed to crocidolite.
Collapse
Affiliation(s)
- A Reid
- School of Population Health, University of Western Australia, Australia
| | | | | | | | | | | |
Collapse
|
50
|
Florio P, Torricelli M, Galleri L, De Falco G, Leucci E, Calonaci G, Picciolini E, Ambrosini G, Linton EA, Petraglia F. High fetal urocortin levels at term and preterm labor. J Clin Endocrinol Metab 2005; 90:5361-5. [PMID: 15956084 DOI: 10.1210/jc.2005-0109] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
CONTEXT Placental urocortin has a role in the cascade of events leading to parturition by stimulating myometrial contractility and placental uterotonins secretion. OBJECTIVE The objective of this study was to evaluate urocortin levels in maternal and fetal [umbilical cord artery (UCA) and vein (UCV)] plasma at term and preterm labor. DESIGN The study design was a controlled cross-sectional study performed from November 2003 to June 2004. SETTING This study was performed at the Division of Obstetrics and Gynecology, University of Siena (Siena, Italy). PATIENTS Plasma samples were collected at term in the absence of labor (TNL; n = 27; 39.3 +/- 0.1 gestational weeks), at term spontaneous vaginal delivery (TL; n = 24; 40.1 +/- 0.2 gestational weeks), and at preterm labor (PTL; n = 19; 32.4 +/- 0.4 gestational weeks). Changes in urocortin mRNA expression were also evaluated in placentas collected from TNL (n = 11), TL (n = 11), and PTL (n = 10). INTERVENTION Urocortin levels were measured by specific RIA. Changes in placental mRNA expression were determined by real-time quantitative RT-PCR analysis. RESULTS Maternal and UCA plasma urocortin levels were significantly (P < 0.0001 for all) higher in TL and PTL than in TNL. Furthermore, UCA concentrations were significantly (P < 0.0001 for all) higher than and correlated with maternal concentrations (TNL: r = 0.45; P < 0.05; TL: r = 0.959; P < 0.0001; PTL: r = 0.7719; P < 0.0001). UCV levels were significantly (P < 0.001) higher in TL and PTL than in TNL and were significantly (P < 0.0001 for all) higher than and significantly (P < 0.0001 for all) correlated with maternal values, but were significantly (P < 0.0001 for all) lower than and correlated with UCA values (TNL: r = 0.9548; P < 0.0001; TL: r = 0.927; P < 0.0001; PTL: r = 0.838; P < 0.0001). Placental urocortin mRNA expression did not differ among TNL, TL, and PTL samples. CONCLUSIONS Fetal urocortin secretion is increased in term and preterm labor. Whether these changes are a consequence rather than a cause of human parturition remains to be addressed.
Collapse
Affiliation(s)
- P Florio
- Department of Pediatrics, Obstetrics, and Reproductive Medicine, University of Siena, Policlinico Le Scotte, viale Bracci, 53100 Siena, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|